3/A

PRIMARY DOCUMENT

Company: Inhibikase Therapeutics, Inc.
Filed: July 15, 2025
Period of Report: June 6, 2025
Accession Number: 0001875620-25-000002

View Document ↗ View on SEC.gov ↗